# Edwin Graaf

> Edwin Graaf is a Series A investor at Gilde Healthcare backing Health Care and Biotechnology. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Gilde Healthcare](https://shizune.co/investors/profile/gilde-healthcare-partners)
- Location: Utrecht, The Netherlands
- Total investments: 8
- Last investment: Jun 2023
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/edwin-de-graaf-ab3190a

Edwin Graaf is a Series A investor at Gilde Healthcare in Utrecht focused on Health Care and Biotechnology. Edwin de Graaf is managing director and general partner of Gilde Healthcare Partners and holds a masters degree in business and fiscal economics from the Erasmus University Rotterdam. He currently serves on the board of Pieris AG and served on the boards of GlycArt AG (trade sale to Roche) and AMT (Euronext: AMT).

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 75% |
| Biotechnology | 5 | 63% |
| Pharmaceutical | 4 | 50% |
| Medical | 3 | 38% |
| Apps | 1 | 13% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 38% |
| Series B | 2 | 25% |
| Series C | 1 | 13% |
| Funding Round | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 1 | 13% |
| Denmark | 1 | 13% |
| Germany | 1 | 13% |
| Switzerland | 1 | 13% |
| United Kingdom | 1 | 13% |

6 countries tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Tagworks Pharmaceuticals | Tagworks Pharmaceuticals is a privately held biotech company based in the Netherlands. Tagworks develops In vivo chemistry to improve the efficacy of cancer therapies and to enable novel approaches in companion diagnostics. The company’s facilities are located at the Radboud University Medical Center in Nijmegen. Founded in 2011, Tagworks is aspin-out of Philips Healthcare, and originates from Philips’ molecular imaging expertise. | $65M | Series A | Jun 22, 2023 |  |
| Withings | Withings is a developer of digital health and wellness smart devices. The company makes a range of products that empower people to make the right decisions for their health. Its digital health and wellness smart devices include a fitness watch that enables users to measure their heart rate. | $60M | Series B | Jul 28, 2020 |  |
| Santaris Pharma | Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug developmentcapabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States. | $12M |  | Jun 21, 2012 |  |
| Prosonix | Prosonix is world leader in the commercialization of proprietary pharmaceutical ultrasonic particle engineering technologies and added value ultrasonic process chemistry solutions. A core expertise is the development of new ‘molecule to particle' methods for manufacture of inhaled medicines. | $21.8M | Series B | May 24, 2012 |  |
| Prosonix | Prosonix is world leader in the commercialization of proprietary pharmaceutical ultrasonic particle engineering technologies and added value ultrasonic process chemistry solutions. A core expertise is the development of new ‘molecule to particle' methods for manufacture of inhaled medicines. | $14.5M | Series B | Jul 06, 2011 |  |
| Santaris Pharma | Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug developmentcapabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States. | $22.4M | Series C | Dec 30, 2007 |  |
| Roche Glycart | Roche Glycart develops antibody drug candidates, which include GA101, a humanized anti-CD20 monoclonal antibody to increase direct- and immune-mediated target cell death; and GA201, a humanized glycoengineered antibody for solid tumors. | $13.6M | Series A | Nov 26, 2003 |  |
| Pieris | Pieris Pharmaceuticals is a clinical-stage biotechnology company that develops drugs to fight cancer, severe asthma, anemia, and other medical conditions with unmet medical needs. The company applies its proprietary Anticalin® technology to the drug development processes. Pieris Pharmaceuticals was founded in 2001 and is based in Freising,Bayern. | $13.2M | Series A | Oct 31, 2002 |  |

8 of 8 investments shown.

## Co-investors
- [Global Life Science Ventures](https://shizune.co/investors/profile/global-life-science-ventures) — VC Fund, 3 deals together
- [Entrepreneurs Fund](https://shizune.co/investors/profile/entrepreneurs-fund) — VC Fund, 2 deals together
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 2 deals together
- [Sunstone Life Science Ventures](https://shizune.co/investors/profile/sunstone-capital-life-science) — VC Fund, 2 deals together
- [Ventech](https://shizune.co/investors/profile/ventech-capital) — VC Fund, 2 deals together
- [ABN AMRO Fund](https://shizune.co/investors/profile/abn-amro) — VC Fund, 1 deal together

## About Gilde Healthcare

VC Fund · Utrecht, The Netherlands

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.

5 contacts available at Gilde Healthcare.

| Name | Title | Profile |
| --- | --- | --- |
| Edwin Graaf | Managing Partner | https://shizune.co/investors/profile/edwin-de-graaf |
| Joep Muijrers | General Partner | https://shizune.co/investors/profile/joep-muijrers |
| Pieter van der Meer | Managing Partner & Founder | https://shizune.co/investors/profile/pieter-van-der-meer |
| Stefan Luzi | Partner | https://shizune.co/investors/profile/stefan-luzi |
| Arthur Franken | Partner | https://shizune.co/investors/profile/arthur-franken |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Edwin Graaf invest in?

Edwin Graaf invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Edwin Graaf last invest?

The most recent investment recorded for Edwin Graaf closed in Jun 2023. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co